Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE-RSV: Maternal Vaccine vs Infant mAb vs Combination for RSV Prevention
NCT07041190Phase 3Not yet recruiting
- Sponsor
- Penta Foundation
- Start
- Sep 2025
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Vaccines & Immunotherapeutics, Engineered Antibody Formats
01
Overview
Phase 3, randomised, open-label trial of RSVpreF vaccine and nirsevimab in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Penta Foundation. Primary endpoint: Symptomatic RSV respiratory tract infection at 12 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
RSVpreF vaccinenirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07041190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041190.